Literature DB >> 29149622

The chemokine receptor type 4 antagonist, AMD3100, interrupts experimental tooth movement in rats.

Kasumi Hatano1, Yuji Ishida2, Hiroyuki Yamaguchi1, Jun Hosomichi1, Jun-Ichi Suzuki1, Risa Usumi-Fujita1, Yasuhiro Shimizu1, Naoki Shibutani1, Sawa Kaneko1, Takashi Ono1.   

Abstract

OBJECTIVE: The aim of this study was to clarify the role of the stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis in osteoclast accumulation, and the influence of orthodontic tooth movement (OTM) under mechanical force application to periodontal tissues, by administration of the CXCR4 antagonist AMD3100.
DESIGN: The upper right first molar (M1) of rats was moved mesially with a 10-g force titanium-nickel closed coil spring. Rats were treated with phosphate-buffered saline or AMD3100 (5mg/kg), which is a SDF-1 antagonist. After 0, 1, 3, and 7days, alveolar bones in all groups were examined at each time point by micro-computed tomography and histological analysis.
RESULTS: Tooth movement was decreased significantly in the AMD3100-treated group at 1, 3, and 7days after beginning OTM. The numbers of tartrate-resistant acid phosphatase-positive multinucleated cells in the periodontal ligament around the maxillary M1 were decreased significantly in the treated as compared to the control group on Days 1 and 3.
CONCLUSION: Administration of AMD3100 decreases OTM and osteoclast accumulation in rat molars under orthodontic force application. These findings suggest that the SDF-1/CXCR4 axis plays an important role in alveolar bone metabolism during OTM.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMD3100; Orthodontic tooth movement; Osteoclast; Periodontal ligament; Stromal cell-derived factor-1

Mesh:

Substances:

Year:  2017        PMID: 29149622     DOI: 10.1016/j.archoralbio.2017.11.003

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  4 in total

Review 1.  Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.

Authors:  Erik De Clercq
Journal:  Antivir Chem Chemother       Date:  2019 Jan-Dec

2.  C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption.

Authors:  Alexander Patera Nugraha; Fumitoshi Ohori; Hideki Kitaura; Adya Pramusita; Saika Ogawa; Takahiro Noguchi; Aseel Marahleh; Yasuhiko Nara; Ria Kinjo; Itaru Mizoguchi
Journal:  Mol Med Rep       Date:  2022-01-11       Impact factor: 2.952

3.  The road of NSCLC stem cells toward bone metastases.

Authors:  Giulia Bertolini; Ilaria Roato
Journal:  Bone Rep       Date:  2022-09-05

4.  Distinct Expression Patterns of Cxcl12 in Mesenchymal Stem Cell Niches of Intact and Injured Rodent Teeth.

Authors:  Pierfrancesco Pagella; César Nombela-Arrieta; Thimios A Mitsiadis
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.